Table 1. Patient characteristics of the MANTRA, MIP, and Combination cohorts.
The 104 patient samples in the Mantra cohort were analyzed using quantitative multiplex immunofluorescence (qmIF) on Mantra and the 81 patients samples in the Melanoma Immune Profile (MIP) cohort were analyzed using nanoString. The patients who overlap between the MANTRA and the MIP cohorts make up the Combination cohort (n=53).
| MANTRA | MIP | Combination | |
|---|---|---|---|
| Clinical characteristics | (n = 104) | (n = 81) | (n = 53) |
| Gender, n (%) | |||
| Male | 75 (72.1) | 62 (76.5) | 40 (75.5) |
| Female | 29 (27.9) | 19 (23.5) | 13 (24.5) |
| Age | |||
| Median, n (range) | 74.5 (22–96) | 67 (22–96) | 68 (22–96) |
| Location of tumor, n (%) | |||
| Trunk | 61 (58.7) | 48 (59.3) | 30 (56.6) |
| Extremity | 41 (39.4) | 32 (39.5) | 22 (41.5) |
| Unknown | 2 (1.9) | 1 (1.2) | 1 (1.9) |
| Stage, n (%) | |||
| II | 91 (87.5) | 63 (77.8) | 42 (72.9) |
| III | 13 (12.5) | 15 (18.5) | 11 (20.8) |
| Pathologic characteristics | |||
| Depth (mm) | |||
| Median, n (range) | 2.5 (0.6–26) | 2.7 (0.7–26) | 2.7 (0.7–11.4) |
| Ulceration, n (%) | |||
| Absent | 36 (34.6) | 32 (39.5) | 19 (35.8) |
| Present | 65 (62.5) | 45 (55.6) | 32 (60.4) |
| Unknown | 3 (2.9) | 4 (4.9) | 2 (3.8) |
| TILs, n (%) | |||
| Absent | 2 (1.9) | 3 (3.7) | 1 (1.9) |
| Non-brisk | 59 (56.8) | 50 (61.7) | 33 (62.3) |
| Brisk | 33 (31.7) | 22 (27.2) | 15 (28.3) |
| Unknown | 10 (9.6) | 6 (7.4) | 4 (7.5) |
| Outcome characteristics | |||
| Patient follow-up (months) | |||
| Median, n (range) | 45 (4–173) | 58 (5–187) | 62 (5–173) |
| Systemic recurrence, n (%) | |||
| Known recurrence | 16 (15.4) | 24 (29.6) | 16 (30.2) |
| No recurrence | 36 (34.6) | 50 (61.7) | 32 (60.4) |
| Unknown | 52 (50) | 7 (8.6) | 5 (9.4) |
| OS (months), n (%) | |||
| Alive (at least 2 years) | 31 (29.8) | 50 (61.7) | 28 (52.8) |
| Dead | 73 (70.2) | 31 (38.3) | 25 (47.2) |
| DSS (months), n (%) | |||
| Alive or NED at death | 42 (40.4) | 62 (76.5) | 39 (73.6) |
| Dead with melanoma | 22 (21.2) | 19 (23.5) | 14 (26.4) |
| Unknown | 40 (38.4) | 0 (0) | 0 (0) |
Abbreviations: DSS, disease-specific survival; NED, no evidence of disease; OS, overall survival; MIP, Melanoma Immune Profile